Joseph Wilson
Family Medicine · Lamar, MONPI 1235169723
Payments from drug & device makers
Across 177 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$737
- Teva Pharmaceuticals USA, Inc.$310
- AbbVie$266
- Lilly USA, LLC$225
- Amgen$217
- Pfizer$183
- plus $762 from 19 others
What the payments were for
- Food & beverage$2,699100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 59 | $737 |
| Teva Pharmaceuticals USA, Inc. | 20 | $310 |
| AbbVie | 16 | $266 |
| Lilly USA, LLC | 14 | $225 |
| Amgen | 12 | $217 |
| Pfizer | 11 | $183 |
| Otsuka America Pharmaceutical, Inc. | 10 | $179 |
| UCB, Inc. | 5 | $80 |
| Johnson & Johnson | 4 | $78 |
| Abbott | 3 | $63 |
| AstraZeneca | 3 | $47 |
| Dexcom, Inc. | 2 | $42 |
| Bayer | 3 | $40 |
| Astellas Pharma US Inc | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Boehringer Ingelheim | 2 | $27 |
| Acera Surgical, Inc. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Organon | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Novartis | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $13 |
| GSK | 1 | $11 |
| Eisai Inc. | 1 | $11 |
How this compares
$2,699 in reported general payments places this provider in the 80th percentile of 2,203 family medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 288 | $166,676 |
| JardianceEmpagliflozin | 175 | $98,343 |
| OzempicSemaglutide | 48 | $54,660 |
| RybelsusSemaglutide | 48 | $48,618 |
| TrulicityDulaglutide | 28 | $36,536 |
| XareltoRivaroxaban | 38 | $35,112 |
| JanuviaSitagliptin Phosphate | 75 | $34,470 |
| RexultiBrexpiprazole | 45 | $29,424 |
| MyrbetriqMirabegron | 34 | $29,393 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $26,465 |
| MounjaroTirzepatide | 24 | $23,612 |
| VraylarCariprazine Hcl | 31 | $21,795 |
| RestasisCyclosporine | 34 | $20,732 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $16,577 |
| Incruse ElliptaUmeclidinium Bromide | 26 | $13,736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $183 | $166,676288 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $27 | $105,637189 claims |
| Novo NordiskOzempic, Rybelsus | $737 | $103,27896 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $225 | $60,14852 claims |
| AbbVieVraylar, Restasis, Linzess | $266 | $50,57379 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $11 | $45,94668 claims |
| Johnson & JohnsonXarelto | $78 | $35,11238 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $179 | $29,42445 claims |
| Astellas Pharma US IncMyrbetriq | $34 | $29,39334 claims |
| AstraZenecaBrilinta, Symbicort | $47 | $19,577102 claims |
| NovartisEntresto | $15 | $7,24920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Lamar
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.